SCHEMBL3515085

SCHEMBL3515085

C[Si](C)(C)CCOCn1cc2ccc([N+](=O)[O-])cc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
NFKB1 P19838 1/20 0.47
CASP3 P42574 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
ALDH1A1 P00352 1/20 0.37
F2RL3 Q96RI0 2/20 0.36
KCNJ1 P48048 1/20 0.36
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18188228 0.91 MAPT (0.41) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2317816 0.79 DGAT1 (0.42) NPC1
SCHEMBL3376854 0.79 KDM4E (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL12670976 0.78 HCAR3 (0.40) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15778085 0.78 NPC1 (0.39) MAPTNPC1MEN1KMT2AALDH1A1
SCHEMBL18896263 0.78 MAPT (0.66) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL29915403 0.77 NPC1 (0.50) NPC1KMT2A
SCHEMBL25592539 0.77 NQO2 (0.36) MAPTLMNAALDH1A1ATM
SCHEMBL1418432 0.76 KDM4E (0.42) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL21316559 0.76 MAPT (0.67) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2010-11-25 US disclosed
EP-2170865-A2 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2010-04-07 EP disclosed
WO-2009010660-A2 SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS WEE1, PRMT1, ABL1 MAPT 2039/4885NPC1 367/4885RAB9A 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.